1.The Effect of A Novel Class Ⅲ Antiarrhythmic Drug-Nifekalant On Action Potential of Atrium And Pulmonary Vein
Hao HAN ; Pihua FANG ; Xiulan LIU
Chinese Journal of Practical Internal Medicine 2006;0(16):-
Objective To investigate the effect of Nifekalant on action potential of atrium and pulmonary vein and the possible clinical efficacy of Nifekalant against atrial tachyarrhythmias.Methods left and right atrium and pulmonary vein removed from 15 white rabbits were made into tissue preparations(0.5 cm?1.5 cm).Action potential was induced by electric stimulation with twofold capture threshold and recorded by standard glass microelectrode technique.Effective refractory periods of left and right atrial and pulmonary vein tissues were measured with burst and programmed stimulation.The Action potentials and effective refractory periods of various tissues were compared between before and after irrigation of Tyrodes fluid containing Nifekalant of 2.13 mg/L.Results After irrigation of Tyrodes fluid containing Nifekalant,APD90 was prolonged[(51?16)ms vs(78?33)ms,P
2.Recent progresses of nonaqueous capillary electrophoresis
Hao WANG ; Xiulan LI ; Huifen LI
International Journal of Biomedical Engineering 2006;0(06):-
As a special branches of capillary electrophoresis(CE), nonaqueous capillary electrophoresis (NACE) was variedly applied in the recent years. A brief summary on solvent properties and molecular interactions in nonaqueous solutions are introduced. Discussing of the approaches employed to enhance and tune selectivity in NACE. Special detection techniques for NACE are presented. Furthermore, a list of relevant applications in biological sample and its metabolin and also in pharmaceutical since 2000 is included, and also take perspective for NACE.
3.Noninvasive prenatal diagnosis ofβ-thalassemia by enriching cell-free fetal DNA in materal plasma
Qingqing WANG ; Yuan ZHANG ; Jun ZHANG ; Xiulan HAO ; Hongying HOU
Chinese Journal of Pathophysiology 2014;(10):1861-1867
AIM:To establish a kind of simple and efficient method for cell-free fetal DNA ( cff-DNA) enrich-ment and to investigate its range of applications and the advantages and disadvantages.METHODS:(1) The single nucleo-tide polymorphisms( SNPs) , which linked to paternalβ-thalassemia mutations, were screened.We analyzed the contact be-tween the SNPs inβ-thalassemia gene ( HBB gene) and haploid type by the Haploview software, and then selected these close SNPs which have higher heterozygosity with the HBB gene.(2) We selected 4 cases of different β-thalassemia muta-tions with their husband, and then we used TT-FAST-COLD-PCR to enrich the IVS-II-654 mutations in maternal plasma.If the IVS-II-654 mutation was not detected, we detected the SNP which linked to the IVS-II-654 mutation.Similarly, we used TT-FULL-COLD-PCR to enrich the CD41-42 mutations in the maternal plasma.At the same time, we used the conventional PCR to enrich CD41-42 mutation and IVS-II-654 mutation in the maternal plasma.RESULTS:(1) Nine cases of the SNP ( rs7480526) linked to the mutation at IVS-II-654 in HBB gene, and 11 cases of the SNP ( rs10768683) linked to the muta-tion at CD41-42 in HBB gene were detected.( 2 ) We detected 1 case who inherited the paternal β-thalassemia mutation (IVS-II-654).We did not directly detect patermal IVS-II-654 mutation in maternal plasma, but detected the SNP linked to the IVS-II-654 mutation in the other case and had 100%detection, and 2 cases inherited the paternal β-thalassemia muta-tions (CD41-42) in the maternal plasma by TT-FULL-COLD-PCR and had 100%detection.However, we detected nothing by conventional PCR.CONCLUSION:TT-COLD-PCR is applicable to enrich cell-free fetal DNA in maternal plasma and is a method in the field of noninvasive prenatal diagnosis.
4.Association between LOXL1 gene polymorphisms and primary open angle glaucoma in Sichuan population.
Bo GONG ; Xiulan LI ; Ning LI ; Fang HAO ; Rong CHEN ; Guangqun ZENG ; Dingding ZHANG
Chinese Journal of Medical Genetics 2015;32(1):89-93
OBJECTIVETo investigate association between the lysyl oxidase-like 1 (LOXL1) gene single nucleotide polymorphism (SNP) and primary open-angle glaucoma (POAG) in Sichuan population.
METHODSIn this study,416 subjects with primary open-angle glaucoma and 997 normal controls were recruited.Three reported LOXL1 tag SNPs (rs1048661,rs3825942 and rs2165241) were genotyped by SNaPshot method.
RESULTSThe study showed that the genotypes of LOXL1 rs1048661,rs3825942 and rs2165241 between POAG and control groups were not statistically significant (OR=1.085, 95%CI 0.92-1.28, P=0.578 for rs1048661; OR=1.059, 95%CI 0.82-1.37, P=0.846 for rs3825942; OR=1.006, 95%CI 0.77-1.32, P=0.966 for rs2165241, respectively). There were no significant difference in allele frequency distribution of LOXL1 rs1048661、rs3825942 and rs2165241 between POAG and normal controls (P=0.322, P=0.660, P=0.965).
CONCLUSIONThe results from the present study do not indicate the association of LOXL1 SNPs (rs1048661, rs3825942 and rs2165241) with POAG in Sichuan population.
Adult ; Aged ; Aged, 80 and over ; Amino Acid Oxidoreductases ; genetics ; Asian Continental Ancestry Group ; genetics ; Glaucoma, Open-Angle ; genetics ; Humans ; Middle Aged ; Polymorphism, Single Nucleotide
5.Research on lightweight model of intelligent-assisted diagnosis of common fundus diseases based on fundus color photography
Bing LU ; Maonian WU ; Bo ZHENG ; Shaojun ZHU ; Xiulan HAO ; Nan CHEN ; Zejiang HOU ; Qin JIANG ; Weihua YANG
Chinese Journal of Ocular Fundus Diseases 2022;38(2):146-152
Objective:To observe the diagnostic value of six classification intelligent auxiliary diagnosis lightweight model for common fundus diseases based on fundus color photography.Methods:A applied research. A dataset of 2 400 color fundus images from Nanjing Medical University Eye Hospital and Zhejiang Mathematical Medical Society Smart Eye Database was collected, which was desensitized and labeled by a fundus specialist. Of these, 400 each were for diabetic retinopathy, glaucoma, retinal vein occlusion, high myopia, age-related macular degeneration, and normal fundus. The parameters obtained from the classical classification models VGGNet16, ResNet50, DenseNet121 and lightweight classification models MobileNet3, ShuffleNet2, GhostNet trained on the ImageNet dataset were migrated to the six-classified common fundus disease intelligent aid diagnostic model using a migration learning approach during training as initialization parameters for training to obtain the latest model. 1 315 color fundus images of clinical patients were used as the test set. Evaluation metrics included sensitivity, specificity, accuracy, F1-Score and agreement of diagnostic tests (Kappa value); comparison of subject working characteristic curves as well as area under the curve values for different models.Result:Compared with the classical classification model, the storage size and number of parameters of the three lightweight classification models were significantly reduced, with ShuffleNetV2 having an average recognition time per sheet 438.08 ms faster than the classical classification model VGGNet16. All 3 lightweight classification models had Accuracy > 80.0%; Kappa values > 70.0% with significant agreement; sensitivity, specificity, and F1-Score for the diagnosis of normal fundus images were ≥ 98.0%; Macro-F1 was 78.2%, 79.4%, and 81.5%, respectively.Conclusion:The intelligent assisted diagnosis of common fundus diseases based on fundus color photography is a lightweight model with high recognition accuracy and speed; the storage size and number of parameters are significantly reduced compared with the classical classification model.
6.Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule.
Yang WANG ; Xiaobin YUAN ; Jiayan XIONG ; Zhidong HAO ; Xingzhe PENG ; Wanlin CHEN ; Lingling CUI ; Hua LI ; Xiulan WANG ; Xiangbo HE ; Min YANG ; Congxin LIANG ; Yongbin MA ; Lieming DING ; Li MAO
Chinese Journal of Lung Cancer 2020;23(8):719-729
Lung cancer is one of the most common malignancies with the highest incidence rate and mortality rate worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85%. Only 5% NSCLC patients are anaplastic lymphoma kinase (ALK) rearrangement positive NSCLC, but the prognosis of these patients is poor, and treatment is urgent. Ensartinib (X-396), a next-generation ALK tyrosine kinase inhibitor (ALK-TKI), has shown greater potency on inhibiting ALK activity and controlling brain metastases than crizotinib, which is indicated for the treatment of crizotinib-resistant, ALK-positive NSCLC patients. Several phase I to III clinical trials included both healthy volunteers and NSCLC patients have been conducted both in China and abroad. In this review, we briefly summarized the results of these trials, and preliminary efficacy, safety, pharmacology and pharmacokinetics/pharmacodynamics of ensartinib were discussed.